alendronate has been researched along with Carcinoma, Hepatocellular in 4 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of hepatocellular carcinoma (HCC) cell line with FTI-277 alone showed cell death in a time and dose dependent manner while in combination with alendronate, a synergistic apoptotic effect at 24 h was observed." | 7.88 | Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study. ( Channa, IS; Hashim, Z; Ilyas, A; Zarina, S, 2018) |
| "Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve." | 7.70 | Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000) |
| "Treatment of hepatocellular carcinoma (HCC) cell line with FTI-277 alone showed cell death in a time and dose dependent manner while in combination with alendronate, a synergistic apoptotic effect at 24 h was observed." | 3.88 | Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study. ( Channa, IS; Hashim, Z; Ilyas, A; Zarina, S, 2018) |
| "Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve." | 3.70 | Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilyas, A | 2 |
| Hashim, Z | 2 |
| Channa, IS | 1 |
| Zarina, S | 2 |
| Cheng, H | 1 |
| Liao, ZL | 1 |
| Ning, LH | 1 |
| Chen, HY | 1 |
| Wei, SS | 1 |
| Yang, XC | 1 |
| Guo, H | 1 |
| Ohnishi, T | 1 |
| Takeda, E | 1 |
| Yogita, S | 1 |
| Miyake, H | 1 |
| Kinoshita, T | 1 |
| Terashima, Y | 1 |
| Matsumoto, T | 1 |
| Tashiro, S | 1 |
4 other studies available for alendronate and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study.
Topics: Alendronate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma | 2018 |
Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective.
Topics: Alendronate; Apoptosis; Azacitidine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2015 |
Alendronate-anchored PEGylation of ceria nanoparticles promotes human hepatoma cell proliferation via AKT/ERK signaling pathways.
Topics: Alendronate; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Ce | 2017 |
Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma.
Topics: Aged; Alendronate; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Hypercalcemia; Liver N | 2000 |